Recursion expects to share Phase II data for REC-994 in the first half of 2025, through a publication, webinar, or presentation at a medical conference. By the end of this year, Recursion plans to ...
Recursion Pharmaceuticals uses AI in drug development, increasing success rates in lab and animal testing, with upcoming data readouts for five Phase 2 programs. The company is a "TechBio," with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results